Intelligence Profile
Research Papers
The research on NAD+ IV infusion remains limited, with only a small number of directly relevant studies available in the scientific literature.
The most pertinent research comes from a pilot study published in Frontiers in Aging Neuroscience in 2019 (PMID: 31572171), which investigated changes in human plasma and urine NAD+ metabolites during a 6-hour intravenous NAD+ infusion. This appears to be one of the few studies specifically examining IV NAD+ administration in humans, though the exact sample size and detailed findings are not provided in the available evidence.
A more recent retrospective pilot study (PMID: 41704678) compared the tolerability of intravenous NAD+ infusion versus oral nicotinamide riboside (NR) in a real-world clinical setting. This study, published in Frontiers in Aging, examined tolerability profiles but specific sample sizes and outcomes are not detailed in the available information.
A systematic review published in Ageing Research Reviews in 2026 (PMID: 41655607) examined NAD+ supplementation for anti-aging and wellness applications, following PRISMA guidelines to analyze both preclinical and clinical evidence. However, this review appears to cover NAD+ supplementation broadly rather than focusing specifically on IV administration.
The remaining studies in the evidence base examine related compounds like nicotinamide mononucleotide (PMID: 34948019) or address unrelated therapeutic areas, providing limited insight into NAD+ IV infusion specifically.
Limitations: The available evidence for NAD+ IV infusion is quite sparse, with most studies focusing on oral NAD+ precursors rather than intravenous administration. The specific methodologies, sample sizes, and detailed outcomes of the relevant studies are not fully available in the provided evidence, limiting the ability to draw comprehensive conclusions about efficacy and safety.
This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any NAD+ therapy.